Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Kenneth Kulmatycki"'
Autor:
Edwin Wong, Carla Nester, Teresa Cavero, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Ute Eisenberger, Maria Jose Soler, David Kavanagh, Erica Daina, Manuel Praga, Nicholas R. Medjeral-Thomas, Anja Gäckler, Clara Garcia-Carro, Andrea Biondani, Frederique Chaperon, Kenneth Kulmatycki, Julie Milojevic, Nicholas J.A. Webb, Prasanna Kumar Nidamarthy, Guido Junge, Giuseppe Remuzzi
Publikováno v:
Kidney International Reports, Vol 8, Iss 12, Pp 2754-2764 (2023)
Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability,
Externí odkaz:
https://doaj.org/article/4142dfa19bbe4b318478e3240af7c53c
Autor:
Nathalie H. Gosselin, Virna J. A. Schuck, Olivier Barriere, Kenneth Kulmatycki, Alison Margolskee, Patrick Smith, YanLing He
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:328-338
Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hyperchole
Autor:
Sara C Humphreys, John A Davis, Sajida Iqbal, Amin Kamel, Kenneth Kulmatycki, Yanbin Lao, Xiumin Liu, John Rodgers, Jan Snoeys, Adam Vigil, Yan Weng, Christopher M Wiethoff, Matthias B Wittwer
Publikováno v:
Nucleic Acids Research. 50:6020-6037
At the time of writing, although siRNA therapeutics are approved for human use, no official regulatory guidance specific to this modality is available. In the absence of guidance, preclinical development for siRNA followed a hybrid of the small molec
Autor:
Antonio Risitano, Régis Peffault de Latour, Eng Soo Yap, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Alexander Roeth, Irina Baltcheva, Julie Milojevic, Niamh Fagan, Kenneth Kulmatycki, Prasanna K Nidamarthy, Guido Junge, Jun Ho Jang
Publikováno v:
Blood. 140:5803-5804
Autor:
Jose Alcantara, Kenneth Kulmatycki, David J. Rowlands, Nicholas J. Simmonds, Lidia Mostovy, Surendra Machineni, Ivan Bottoli, Phaninatha Sarma Ayalavajjala, Robert M. Strieter, Henry Danahay, Shamsah Kazani, Raju Vegesna, Jerry A. Nick, Ieuan Jones, Mohammed Salman, Steven M. Rowe, Ian Nicholls, Martin Gosling, Julie Milojevic, Jeroen Verheijen
Publikováno v:
Journal of Cystic Fibrosis. 20:250-256
Background This is the first-in-human study of icenticaftor, an oral potentiator of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) channel. Restoration of CFTR activity has shown significant clinical benefits, but more studies ar
Autor:
Stephen Gleason, Katy A Hayes, Denise Yates, Mark T. Dransfield, Steven M. Rowe, Martin Gosling, Nazmul Haque, David J. Rowlands, Ieuan Jones, Henry Danahay, Kenneth Kulmatycki, Sarah Schmidt Grant
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 15:2399-2409
Rationale Excess mucus plays a key role in COPD pathogenesis. Cigarette smoke-induced cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction may contribute to disease pathogenesis by depleting airway surface liquid and reducing mucoci
Autor:
Jin Chen, Jonathan S. Dosik, Douglas C. Bauer, Kenneth Kulmatycki, Yuming Chen, Dan Meyers, Adele Noe, Rachel L. Soon
Publikováno v:
Photochemical & Photobiological Sciences. 15:1155-1162
The DGAT1 inhibitor, pradigastat, demonstrated a mild phototoxicity signal in preclinical studies. Therefore, this clinical trial was conducted to assess the risk of photosensitivity in humans. 47 healthy adults were randomized to part A (double-blin
Autor:
Srikanth Neelakantham, Tapan K. Majumdar, Aishwarya Movva, Atish Salunke, Charles D. Meyers, Kenneth Kulmatycki, Anne Crissey, Jin Chen, Adele Noe
Publikováno v:
Clinical Pharmacology in Drug Development. 5:450-459
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To evaluate the effects of supratherapeutic concentrations of pradigastat on the QTc interval, 2 studies were conducted. The first
Autor:
Kenneth Kulmatycki, Atish Salunke, Yan-Ling He, Hikoe Suzuki, Sachiko Mita, Shripad D. Chitnis, Wei Zhou
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 54:305-314
Objective To assess the bioequivalence of vildagliptin/metformin fixeddose combination (FDC) tablets (50/250 mg and 50/500 mg) to free combinations of vildagliptin and metformin and the effect of food on the pharmacokinetics (PK) of vildagliptin and
Autor:
Meike Scharenberg, Serge Côté, Carsten Krantz, Craig T. Basson, Keith DiPetrillo, Stefan Ewert, Janeen M Salter, Brian Stoll, Geraldine Horny, Simone Schleeger, Yu-Hsin Chiu, Julie DeGagne, Peter Hoffmann, Andreas Hein, Jianying Yu, Peter McCormack, Zhiping Chen, Paul Ramage, Nikolaus Schiering, Frederic Villard, Yasser Khder, Samu Melkko, Jörg Eder, Ulrich Hassiepen, Yiming Zhang, Lionel Muller, Xueming Huang, Robert J. A. Frost, Kenneth Kulmatycki, Alexander W. Koch, David Louis Feldman
Publikováno v:
Blood. 133(13)
A large unmet medical need exists for safer antithrombotic drugs because all currently approved anticoagulant agents interfere with hemostasis, leading to an increased risk of bleeding. Genetic and pharmacologic evidence in humans and animals suggest